These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30678509)

  • 1. Targeting angiogenesis in metastatic renal cell carcinoma.
    Canino C; Perrone L; Bosco E; Saltalamacchia G; Mosca A; Rizzo M; Porta C
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):245-257. PubMed ID: 30678509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
    Sawhney R; Kabbinavar F
    Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
    Gao X; McDermott DF; Michaelson MD
    Oncologist; 2019 Jun; 24(6):725-727. PubMed ID: 31036769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From oxygen sensing to angiogenesis: Targeting the hypoxia signaling pathway in metastatic kidney cancer.
    Chung C
    Am J Health Syst Pharm; 2020 Dec; 77(24):2064-2073. PubMed ID: 33016992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the importance of smart drugs in renal cell carcinoma.
    Patard JJ; Rioux-Leclercq N; Fergelot P
    Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy for renal cell cancer: what are possible options?
    Santos N; Wenger JB; Havre P; Liu Y; Dagan R; Imanirad I; Ivey AM; Zlotecki RA; Algood CB; Gilbert SM; Allegra CJ; Okunieff P; Vieweg J; Dang NH; Luesch H; Dang LH
    Oncology; 2011; 81(3-4):220-9. PubMed ID: 22085914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma.
    Joshi S; Singh AR; Durden DL
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):595-608. PubMed ID: 25578041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
    Hutson TE; Sonpavde G; Galsky MD
    Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
    Alonso-Gordoa T; García-Bermejo ML; Grande E; Garrido P; Carrato A; Molina-Cerrillo J
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
    Ainsworth NL; Lee JS; Eisen T
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
    Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U
    Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648
    [No Abstract]   [Full Text] [Related]  

  • 14. Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.
    Porta C; Toscani I; Czarnecka AM; Szczylik CA
    Expert Opin Biol Ther; 2017 Feb; 17(2):151-162. PubMed ID: 27960591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents.
    Choueiri TK
    Clin Genitourin Cancer; 2008 Mar; 6(1):15-20. PubMed ID: 18501077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
    Golshayan AR; Brick AJ; Choueiri TK
    Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic therapy in renal cell carcinoma.
    Sharma SG; Nanda S; Longo S
    Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):77-83. PubMed ID: 19601920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.